<DOC>
	<DOC>NCT00735904</DOC>
	<brief_summary>This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer</brief_summary>
	<brief_title>Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically or cytologicallyconfirmed diagnosis of squamous NSCLC Stage IIIB with malignant effusion (fluid cytology demonstrating malignant cells required), Stage IV, or recurrent disease after definitive local therapy Candidate for primary treatment with cisplatin and gemcitabine Presence of measurable disease by RECIST Adequate organ function as defined by the following criteria: ECOG performance status of 0 or 1 Prior systemic treatment for Stage IIIB (with malignant effusion) or Stage IV NSCLC. One or more lung lesions with cavitation, or any lesion invading or abutting a major blood vessel as assessed by CT or MRI. History of hemoptysis &gt; Â½ tsp (2.5 ml) of blood per day for a day or more within 1 week of study treatment, or Grade 3 or 4 hemoptysis within 4 weeks of study treatment NCI CTCAE Grade 3 hemorrhage from any cause within 4 weeks of study treatment Preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. Untreated brain metastases. Need for therapeutic anticoagulation, regular use of aspirin (&gt; 325 mg/day), NSAID or other medications known to inhibit platelet function.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>AG-013736</keyword>
	<keyword>axitinib</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>NSCLC</keyword>
	<keyword>squamous cell</keyword>
	<keyword>lung cancer</keyword>
</DOC>